2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-159737
    Rociclovir 108436-80-2 98%
    Rociclovir (HOE 602) is an acyclic nucleoside derivative. Rociclovir protects mice against HSV and MCMV infections, but lacks antiviral activity in cell cultures.
    Rociclovir
  • HY-159823
    Suricapavir 2417270-21-2 98%
    Suricapavir is a potent viral replication inhibitor. Suricapavir shows antiviral activity.
    Suricapavir
  • HY-159828
    Dezecapavir 2570323-59-8 98%
    Dezecapavir (example 4) is a potent inhibitor of HIV replication, with the EC50 of 0.025 nM and CC50 of ＞0.5 μM in MT2 cells.
    Dezecapavir
  • HY-159862
    IM21.7c 2416939-42-7 98%
    IM21.7c is a cationic lipid that can be used to synthesize lipid nanoparticles (LNP) for delivering mRNA and other payloads.
    IM21.7c
  • HY-159879
    AAK1-IN-6 3061058-16-7 98%
    AAK1-IN-6 (Compound 23) is an inhibitor of AP-2-associated protein kinase 1 (AAK1, IC50 = 12 nM) with antiviral activity against the dengue virus (DNEV2, EC50 = 0.24 μM) and Venezuelan equine encephalitis virus (VEEV, EC50 = 0.30 μM). AAK1-IN-6 can be utilized in antiviral research.
    AAK1-IN-6
  • HY-159883
    DDHF20 98%
    DDHF20 is an antimicrobial agent against Staphylococcus aureus, targeting and inhibiting its thioredoxin reductase (TrxR). It acts as a competitive inhibitor for the NADPH binding site. DDHF20 is expected to be used in research related to antimicrobial infections caused by Staphylococcus aureus.
    DDHF20
  • HY-159900
    Antimalarial agent 46 2715225-19-5 98%
    Antimalarial agent 46 (Compound 42a) is an antimalarial agent with antimalarial activity. Antimalarial agent 46 shows inhibitory activity against P. falciparum lines.
    Antimalarial agent 46
  • HY-159915
    Se2h 98%
    Se2h is a cruzain inhibitor that exhibits strong activity against the intracellular amastigotes of Trypanosoma cruzi (EC50 < 1 μM, SI > 10), with an inhibitory activity against cruzain of IC50 < 100 nM (SI > 5.55). Compared to Benznidazole (HY-B1548) and the cruzain inhibitor K777 (HY-119293), Se2h shows superior selectivity and inhibition, while its selenazole structure reduces selenium-related toxicity. Se2h exhibits antiparasitic activity and holds promise for research in Chagas disease.
    Se2h
  • HY-159929
    Antibiotic adjuvant 2 98%
    Antibiotic adjuvant 2 (compound 5q) is an antibiotic adjuvant with potent colistin-potentiating activity and low mammalian toxicity. Antibiotic adjuvant 2 has minimum re-sensitizing concentration of 0.125 μg/mL agnist of Escherichia coli AR-0493.
    Antibiotic adjuvant 2
  • HY-159930
    Antibiotic adjuvant 3 2972593-21-6 98%
    Antibiotic adjuvant 3 (compound 8g) is an antibiotic adjuvant with potent colistin-potentiating activity and low mammalian toxicity. Antibiotic adjuvant 3 has minimum re-sensitizing concentration of 0.25 μg/mL agnist of Escherichia coli AR-0493.
    Antibiotic adjuvant 3
  • HY-159932
    SARS-CoV-2 Mpro-IN-30 98%
    SARS-CoV-2 Mpro-IN-30 (compound L2) is a SARS-CoV-2 Mpro with the IC50 of 9.1 nM.
    SARS-CoV-2 Mpro-IN-30
  • HY-159933
    SARS-CoV-2-IN-105 98%
    SARS-CoV-2-IN-105 (Compound 4a) is a SARS-CoV-2 inhibitor with the EC50 of 0.69 μM.
    SARS-CoV-2-IN-105
  • HY-159960
    Carbonic anhydrase inhibitor 28 98%
    Carbonic anhydrase inhibitor 28 (Compound 11) is a Pseudomonas aeruginosa carbonic anhydrase inhibitor. Carbonic anhydrase inhibitor 28 exhibits antimicrobial activity, with a MIC of 0.5 μg/mL and a MBC of 1 μg/mL against P. aeruginosa. Carbonic anhydrase inhibitor 28 can be used in anti-infection research.
    Carbonic anhydrase inhibitor 28
  • HY-159961
    SARS-CoV-2 Mpro-IN-34 98%
    SARS-CoV-2 Mpro-IN-34 (Compound 26) is an inhibitor for SARS-CoV-2 Mpro with an IC50 of 6 nM. SARS-CoV-2 Mpro-IN-34 exhibits inhibitory efficacy against OC43 Mpro with an IC50 of 33 nM. SARS-CoV-2 Mpro-IN-34 exhibits antiviral activity in SARS-CoV-2 infected Vero E6 cell with an EC50 of 0.103 μM.
    SARS-CoV-2 Mpro-IN-34
  • HY-159963
    PfCLK3-IN-1 98%
    PfCLK3-IN-1 (Compound 4) is a covalent inhibitor for Plasmodium falciparum CLK3 (Pf CLK3) under alkaline conditions with an pEC50 of 7.1. PfCLK3-IN-1 reduces mature gametocytes in sexual stage parasites, and prevents transmission. PfCLK3-IN-1 inhibits P. falciparum Dd2-B2 clone with an IC50 of 239.5 nM.
    PfCLK3-IN-1
  • HY-159984
    HIV-1 inhibitor-78 98%
    HIV-1 inhibitor-78 (compound 15f) is a potent and broad-spectrum non-nucleoside reverse transcriptase inhibitor, with an EC50 of 3 nM for wild-type HIV-1. HIV-1 inhibitor-78 can be used for the research of HIV infection.
    HIV-1 inhibitor-78
  • HY-159985
    Jun13728 98%
    Jun13728 is a potent and covalent SARS-CoV-2 papain-like protease inhibitor, with an IC50 of 0.1 μM. Jun13728 can be used for SARS-CoV-2 antiviral research.
    Jun13728
  • HY-160168
    BTK-IN-31 2662512-02-7 98%
    BTK-IN-31 (Compound 2) is a selective, non-covalently reversible, and blood-brain barrier (BBB) permeable Btk inhibitor. BTK-IN-31 has research potential in immune disorders, cancer, cardiovascular disease, viral infections, inflammation, metabolic/endocrine dysfunction, and neurological disorders.
    BTK-IN-31
  • HY-160446
    BET-IN-24 2407658-21-1 98%
    Bet-in-24 (example 2) is a bromodomain and extra-terminal (BET) inhibitor. BET-IN-24 can be used in the study of virology, heart failure, inflammation, central nervous system (CNS) diseases and many cancers
    BET-IN-24
  • HY-16050R
    Plitidepsin (Standard) 137219-37-5
    Plitidepsin (Standard) is the analytical standard of Plitidepsin. This product is intended for research and analytical applications. Plitidepsin (Aplidine) is a potent anti-cancer agent by targeting eEF1A2 ( KD=80 nM). Plitidepsin possesses antiviral activity and is against SARS-CoV-2 with an IC90 of 0.88 nM. Plitidepsin is usually used for multiple myeloma and advanced cancer research, and has the potential for COVID-19 research.
    Plitidepsin (Standard)
Cat. No. Product Name / Synonyms Application Reactivity